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Introduction 
Despite advances in treatment, mortality of individuals with diabetes remains 
higher than the general population, mainly due to increased risk of cardiovascular 
(CV) events (1). The higher CV mortality in diabetes, often secondary to coronary 
artery disease (CAD), is mainly related to two factors: i) premature and advanced 
atherosclerosis and ii) increased thrombosis potential. The former is usually 
treated with revascularisation following an acute event (provided the affected 
vessel is accessible) followed by multifactorial medical therapy to optimise blood 
pressure and lipid parameters together with appropriate management of 
glycaemia (2). Despite the enhanced thrombotic environment in diabetes, anti-
thrombotic therapy in this population appears to be largely similar to those with 
normal glucose metabolism, posing the question: is this practice clinically 
justified? 
Antithrombotic treatment in diabetes can be divided into primary prevention in 
those without previous history of CV disease and secondary prevention in 
individuals who previously sustained a vascular event.  
 
Primary prevention 
Earlier guidelines advocated initiation of antiplatelet therapy, usually using aspirin, 
in individuals with diabetes and no cardiovascular history. This advice was mainly 
based on data from post hoc analysis of historical studies, conducted in the pre-
statin era (3;4). However, this practice has changed after some high profile, if 
woefully underpowered, studies suggested that aspirin is not an effective primary 
prevention agent in diabetes (5;6). A number of subsequent meta-analyses failed 
to show a clinically favourable benefit/risk ratio for aspirin in diabetes, dampening 
any residual enthusiasm for widespread use of this agent in primary prevention 
(7-11). The relatively recent ESC/EASD and ADA guidelines quite rightly 
emphasised the lack of robust evidence for or against such a practice and adopted 
a pragmatic approach by advocating that antiplatelet therapy for primary 
prevention in diabetes can be offered to higher risk patients (level of evidence 
IIbC) without clearly defining this subgroup (2;12). The simple truth is that 
adequately powered studies to address the role of aspirin, or any other antiplatelet 
therapy, in primary CV protection in diabetes have not been undertaken until 
recently and results of these trials, such as ASCEND (NCT00135226) and ACCEPT-
D (ISRCTN48110081), are eagerly awaited. Until these data become available, 
routine use of antiplatelet agents for primary vascular protection should be 
avoided. 
 
Secondary prevention 
This can be divided into medium and long term prevention following the vascular 
event. It can be argued that a third category exists related to antithrombotic 
treatment during the acute vascular event but this is beyond the scope of the 
current editorial. 
Medium term treatment usually lasts for 12 months following a coronary event 
and relies on dual antiplatelet therapy (DAT) employing two agents that modulate 
different pathways in platelet activation. These consist of an inhibitor of the 
thromboxane pathway, aspirin, and one of the P2Y12 inhibitors clopidogrel, 
prasugrel or ticagrelor.  Long-term therapy, beyond one year, employs a single 
antiplatelet agent, usually aspirin, which is continued for life. However, the best 
treatment strategy in diabetes is far from clear despite a number of recent large 
multicentre trials.  
In the TRITON-TIMI 38 study, involving 13608 patients with acute coronary 
syndrome, the composite primary end point (PEP) of CV mortality, non-fatal 
myocardial infarction or stroke was lower with the combination of prasugrel and 
aspirin (9.9%) than clopidogrel and aspirin (12.1%; p<0.001) but the increase in 
bleeding events cancelled out the clinical benefit (2.4% and 1.8%, respectively; 
p=0.03). However, analysis of the diabetes subgroup (n=3146) showed a greater 
reduction in PEP with prasugrel and aspirin compared with clopidogrel and aspirin 
(17.0% and 12.2%, respectively; p<0.001) without an increased risk of bleeding 
(13). The PLATO study (n=18624) showed superiority of ticagrelor and aspirin 
compared with clopidogrel and aspirin following acute coronary syndrome, an 
observation that was maintained in diabetes patients (n=4662), although strictly 
speaking the difference in this subgroup failed to reach statistical significance (14).  
These studies strongly suggest that clopidogrel is not the best P2Y12 inhibitor 
when used in combination therapy in patients with diabetes.  
Unfortunately, a specific and adequately powered DAT study in diabetes patients 
with ACS is yet to be conducted and current data have been obtained following 
subgroup analysis of trials including a combination of diabetes and non-diabetes 
individuals. The ESC/EASD guidelines highlighted the superiority of modern P2Y12 
inhibitors and encouraged the use of these agents for DAT in diabetes (2). It 
should be noted that the beneficial effect of prasugrel is mainly evident in patients 
undergoing percutaneous coronary intervention (PCI) and therefore this treatment 
is not recommended for patients who do not undergo revascularisation (15). A 
recent metaanalysis further suggested that DAT with prasugrel may be the best 
option in patients with diabetes, particularly those undergoing PCI, emphasising 
superiority of this agent compared with clopidogrel (16). 
 
What about long-term secondary CV prevention in diabetes? Current practice 
dictates lifelong antiplatelet monotherapy, usually with aspirin, after the initial 
phase of DAT in those sustaining a coronary event (class of evidence IA according 
to EASD/ESC guidelines). However, several pieces of evidence suggest that this 
treatment is suboptimal in patients with diabetes. Almost 15 years ago, Bhatt and 
colleagues demonstrated that long-term monotherapy with clopidgrel is superior 
to aspirin in diabetes, particularly in those with longer diabetes duration requiring 
insulin therapy (17). Naturally, this was not a definitive study, as it was based on 
a post hoc analysis, but it is surprising that this was not investigated further at 
the time in a definitive trial. This will be rectified to some extent by investigating 
the effects of ticagrelor monotherapy following acute coronary syndrome and PCT 
in the LEADERS-GLOBAL trial, which is ongoing and includes a decent sized 
population of diabetes patients (18).  
Others have suggested that once daily aspirin is less effective than twice daily 
dosing in diabetes, given the short half-life of aspirin and the high platelet turnover 
in this condition (19). Outcome studies investigating the role of twice daily aspirin 
in diabetes would be of interest but funding to undertake such work may prove to 
be difficult. More recently, a study has shown that longer term therapy with aspirin 
and ticagrelor in 6806 diabetes patients with established CAD (for a median of 33 
months) reduced major adverse cardiac events compared with aspirin alone (20), 
suggesting that DAT should be continued beyond 12 months of the coronary event, 
adding yet another dimension to long-term antiplatelet therapy in diabetes. 
Is it all about antiplatelet therapy? 
In the absence of cardiac arrhythmias and valvular heart disease, prevention of 
coronary thrombosis mainly relies on antiplatelet therapy. However, coagulation 
proteins are affected in diabetes resulting in fibrin networks (the backbone of 
blood clots) that are compact and difficult to breakdown, contributing to an 
enhanced thrombotic environment (21). Clinical studies targeting fibrin networks 
as a way of preventing CAD have been scarce and used in combination of DAT, 
failing in the process to show a benefit, largely due to increased bleeding events 
[summarised in (22)]. Current agents targeting coagulation proteins have a 
relatively broad inhibitory activity by modulating FX or thrombin activity, 
consequently resulting in profound inhibition of fibrin network formation that in 
turn increases bleeding risk. A more targeted approach may prove to be both safer 
and more effective. For example, studies have shown increased incorporation of 
antifibrinolytic proteins into clots from patients with diabetes. Plasmin inhibitor 
and complement C3 incorporation into fibrin clots of patients with diabetes is 
increased, which in turn compromises fibrin clot lysis and predisposes to 
thrombosis (23;24). Targeting the interaction between fibrinogen and anti-
fibrinolytic proteins may offer an alternative antithrombotic strategy in diabetes 
that is disease specific and perhaps safer than the broad inhibition of fibrin network 
formation by agents targeting FX and thrombin.   
 
Future directions 
There are a number of measures to be considered in order to optimise 
antithrombotic therapy in diabetes. Firstly, adequately powered clinical studies in 
individuals with diabetes are needed, rather than drawing conclusions from 
subgroup analysis of large studies, including mixed populations of diabetes and 
non-diabetes patients. Carefully designed diabetes studies, conducted in 
collaboration between cardiologists and diabetologists, will allow appropriate 
characterisation of patients with the possibility of identifying diabetes subgroups 
who would most benefit from a particular intervention. Secondly, more studies are 
required to understand the best strategy for long-term antithrombotic therapy in 
diabetes. This is likely to encompass a large programme of work that includes 
alternative dosing of existing agents, use of low dose combination antiplatelet 
therapies and low dose combination of anti-platelet and anticoagulant therapies. 
The latter is a particularly attractive concept DV³PLOG´LQKLELWLRQRIERWKWKHFHOOXODU
and protein phase of coagulation may prove to be more effective at reducing 
thrombosis risk while limiting bleeding complications. Thirdly, research into 
alternative antithrombotic therapies offers another avenue to control the 
enhanced thrombosis risk in diabetes. For instance, FXII inhibitors have been 
claimed to offer protection from thrombosis with minimal risk of bleeding (25). 
Such an approach may be particularly useful in clinical scenarios involving 
activation of the intrinsic pathway (such as stent thrombosis) but perhaps less 
effective in conditions involving plaque rupture (which involves activation of the 
extrinsic pathway). Diabetes-specific therapies involving modulation of 
antifibrinolytic protein incorporation into fibrin networks offer the novel possibility 
of tackling head on one of the pathophysiological mechanisms in diabetes that 
enhances the thrombotic milieu.  
Finally, we are in desperate need of a measure that accurately identifies 
thrombosis potential in individuals at risk of coronary artery disease. We regularly 
measure response to antihypertensive or lipid therapies with subsequent 
modification of treatment according to the response of each patient. In contrast, 
antithrombotic therapy is given to patients and the prescribing physician simply 
³KRSHs IRUWKHEHVW´without properly assessing response to these agents. It is 
well accepted that platelet reactivity can predict future ischaemic events but 
modification of treatment according to platelet function testing failed to improve 
outcome in a large study (26), leading some to conclude that such an approach is 
not clinically viable. Collet and colleagues should be applauded for their efforts but 
the study is far from conclusive; thrombosis risk should not rely on a single 
measurement and more work is needed to identify a reliable marker of the 
thrombotic milieu, which is likely to include multiple measures of thrombosis. 
 
Conclusions 
Although modulation of thrombosis risk in individuals with CAD has been 
fundamental at reducing future ischaemic events and mortality, current therapies 
are yet to be optimised, particularly in patients with diabetes. The enhanced 
thrombotic environment in diabetes calls for alternative antithrombotic treatment 
strategies in this group both in primary and secondary vascular protection. An 
often overlooked difficulty is that diabetes is not a single disease entity but a 
continuum of different conditions with variable vascular risk dependent on a 
number of factors such as diabetes duration, type of hypoglycaemia therapy and 
presence of microvascular complications. Therefore, the benefit of antithrombotic 
therapy, particularly in primary prevention, is likely to be different according to 
the individual vascular risk of each patient. Therefore, treatment to reduce 
thrombosis risk may need to be varied in subgroups of diabetes patients in order 
to achieve the best benefit/risk ratio. 
A combination of basic, translational and clinical research studies to identify 
accurate markers of thrombosis and develop novel antithrombotic compounds will 
help to effectively control the thrombotic environment in diabetes. Moreover, 
studies investigating different doses of existing agents and various antithrombotic 
combination therapies is perhaps necessary to maximise benefits in this high risk 
group. One thing for sure, there is still a long way to go in order to optimise 
antithrombotic therapy in patients with diabetes and we have thus far merely 
scraped the surface of this highly complex area. 
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